BMY News and Press, Bristol-Myers Squibb Company From 02/24/26

2026-02-24 09:35:33 ET Late-Stage Pipeline Advancements and Novel Therapies Position Sector for Accelerated Growth and Major Value Catalysts New York, NY –February 24, 2026 – Market News Updates News Commentary – Mental health disorders—in...

2026-02-20 15:21:00 ET More on pharmaceutical companies Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Pfizer: Recovery Isn't Over, Battered Valuation St...

2026-02-20 11:40:07 ET More on Bristol-Myers Squibb Company, Dr. Reddy's Bristol-Myers: I'm Buying Post Earnings Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff NIH director rep...

2026-02-19 17:20:00 ET Listen here or on the go via Apple Podcasts and Spotify Next-gen investing experts Julia Ostian , Jack Bowman , and Kenio Fontes share their investment strategies (0:30) Rare earths and precious metals (2:20) Amazon, Apple, AMD and ...

2026-02-19 17:01:00 ET It isn't easy to find bargains on the stock market these days. According to a recent analysis by FactSet , the average forward price-to-earnings ratio (P/E) for the S&P 500 index currently stands at 21.5, which is notably above the 17.6 ratio it stood at 1...

2026-02-19 16:09:02 ET Introduction Read the full article on Seeking Alpha For further details see: Bristol-Myers: I'm Buying Post Earnings

2026-02-19 13:31:04 ET More on AbbVie, AstraZeneca PLC, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable AbbVie: Dominating Immunology While Building Oncology Upside Merck posts n...

2026-02-19 12:35:00 ET Healthcare is a multi-trillion-dollar industry in the United States alone. With 2024 spending exceeding $5.3 trillion, the sector is nearly one-fifth of the U.S. economy. That alone justifies holding several healthcare stocks in your long-term portfolio, though it can...

2026-02-19 11:28:56 ET Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , " Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.... R...

2026-02-18 14:13:52 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game Pfizer: The Rebound Looks Unsustainable Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction ...